TauRx Therapeutics to present at Social Care Conference in London on 25th March

TauRx Therapeutics to present at Social Care Conference in London on 25th

TauRx Chairman and London-based principal investigator will highlight how access to investigational treatments for Alzheimer’s is changing the care model for people with cognitive impairment – now and in the future   

LONDON, 24 March 2014 – TauRx Therapeutics Ltd, a University of Aberdeen spin-out and privately held company, announced today that its Chairman, Professor Claude Wischik, will be presenting at the upcoming Social Care Conference on 25th March at 12:35 pm at The Brewery Conference Centre in London.

The Social Care conference, to be attended by up to 350 NHS representatives, local government and healthcare professionals in social care, continues the momentum started with the G8 Dementia Research Summit in December and subsequent announcements by Jeremy Hunt, such as a new initiative to speed up the timeframe that patients can access innovative medicines following positive clinical trial results.

In a special breakout session, Professor Wischik and Dr Emer MacSweeney, a consultant neuroradiologist, principal investigator and CEO of Re:Cognition Health, will share their views on the question of how close we are to making Alzheimer’s disease a long-term manageable illness for the 800,000 people currently diagnosed with dementia in the UK and hundreds of thousands more suspected of having earlier (undetectable) stages of the disease.

Professor Wischik will provide an update on the company’s global Phase 3 clinical trials involving an entirely new approach to treating Alzheimer’s, by targeting tau tangles that accumulate in the brain leading to cognitive degeneration. The studies build on nearly 30 years of research by Prof. Wischik and colleagues with promising Phase 2 results suggesting the investigational  Tau Aggregation Inhibitor (TAI), LMTX™, can halt or slow the progression of mild to moderate Alzheimer’s, as well as Frontotemporal Dementia (FTD), also known as Pick’s Disease. It is hoped that TauRx’s disease modifying drug will be a significant step in allowing people with Alzheimer’s to live their lives without dementia.

Patients and carers can find more information about the clinical research studies by visiting www.alzheimersglobalstudies.net and www.ftdstudy.net.

 ###

Media Contacts:

Sylvie Berrebi: +44 (0)7795 197271; sylvie@sciad.com / Elizabeth Puller: +44 (0)208 834 1447; press@taurx.com

 

Notes to editors:

  • About TauRx Therapeutics: TauRx Therapeutics Ltd is a spin-out company from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company’s tau aggregation inhibitor, LMTX™, is currently in global Phase 3 clinical trials for Alzheimer’s and Frontotemporal Dementia (FTD). LMTX™ targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to tangles. TauRx’s primary research facilities are in Aberdeen. For more information, please visit: http://www.taurx.com 

 

  • About The Social Care Conference:‘Care for all’, the 2nd National Social Care Conference and Exhibition, is set to examine how reforms to the healthcare provision across the nation have affected the services delivered. The conference will provide a platform for the dissemination of learning and best practice, and a showcase of productivity and innovation. For more information, please visit: http://www.socialcarereform.co.uk/event-home